NCT06638307 2026-03-11
A First-in-Human Study of MEN2312 in Adults With Advanced Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Recruiting
Clinical Trials
10 trialsNCT05386108 2026-02-05
ELECTRA
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT05563220 2026-01-06
ELEVATE
Stemline Therapeutics, Inc.
Phase 1/2 Recruiting
NCT03778931 2025-09-15
EMERALD
Stemline Therapeutics, Inc.
Phase 3 Completed
NCT05596409 2025-06-05
ELCIN
Stemline Therapeutics, Inc.
Phase 2 Active not recruiting
NCT05618613 2025-05-09
ELONA
Context Therapeutics Inc.
Phase 1/2 Terminated
NCT06544577 2024-08-09
Safety of Elacestrant in ER+/HER2- and ESR1 Mutations MBC
SciClone Pharmaceuticals
Recruiting
NCT04791384 2023-07-27
Phase Ib/II Trial of Abemaciclib and Elacestrant in Patients With Brain Metastasis Due to HR+/Her2- Breast Cancer
Criterium, Inc.
Phase 1/2 Unknown
NCT02338349 2022-08-18
A Phase I, Multicenter, Open-Label, Multi-Part, Dose-escalation Study of RAD1901 in Postmenopausal Women With Advanced Estrogen Receptor Positive and HER2-Negative Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed
NCT02650817 2022-08-18
Phase IB Study to Evaluate RAD1901 on the Availability of Estrogen Receptor Binding Sites in Metastatic Breast Cancer
Stemline Therapeutics, Inc.
Phase 1 Completed